Johnson & Johnson Beats Q3 Earnings, Revenue Estimates

Johnson & Johnson beat earnings and revenue estimates in the third quarter. The company posted earnings of $2.05 per share, beating estimates of $2.03 per share.

Johnson & Johnson has surpassed earnings-per-share estimates four times. In the third quarter, the company posted net sales of $20.35 billion, surpassing estimates by 2.19%. During the same quarter last year, the company posted revenues of $19.65 billion. Johnson & Johnson topped revenue estimates three times in the last four quarters.

Third-quarter net income came in at $3.93 billion, or $1.44 per share, up from $3.76 billion.

The company’s pharmaceuticals segment generated $10.35 billion in revenue, beating estimates of $10.02 billion. Sales of medical devices hit $6.59 billion, which missed expectations of $6.64 billion. Consumer sales came in at $3.42 billion in sales, beating estimates of $3.34 billion.

Third-quarter sales of Darzalex, the company’s cancer drug, hit $498 million. Sales failed to meet analyst estimates of $538.7 million. Sales of Stelara, an immunotherapy treatment designed for plaque psoriasis, hit $1.31 billion. Analysts were expecting sales to hit $911 million.

Johnson & Johnson, which owns over 275 companies in 60 nations, adjusted its full-year forecast to $8.13-$8.18 per share. The adjusted forecast is up from $8.07-$8.17 per share. Wall Street is expecting full-year earnings of $8.15 per share. Revenue is projected to come in at $81-$81.4 billion. Analysts were expecting revenue of $81.21 billion.

Earlier in the month, Johnson & Johnson entered an agreement with Arrowhead Pharmaceuticals to develop a Hepatitis B treatment and to take a minority stake in the company. The deal could be worth over $3.7 billion.

Johnson & Johnson’s relaunch of its baby care line has helped drive sales. The company had been losing ground in this market due to niche upstart brands and was facing a 20% decline in sales since 2011. Sales of baby care increased 20% to $120 million, up from $100 million in the same period last year.

As part of its relaunch, the company cut the number of ingredients in its products in half, removed sulfates and dyes, and replaced ingredients like mineral oil with coconut oil. The packaging was also redesigned, adding pumps to many products to make them easier for parents to use while holding the baby.

Although Johnson & Johnson surpassed expectations with sales and revenue, the company’s stock is still down 4.1% since the start of the year. The S&P 500, by comparison, has gained 2.9% during the same period.

Hot this week

Did David Wineland and Serge Haroche Steal Idea For The Nobel Physics Prize?

Dr. Omerbashich says the Royal Swedish Academy is a Crime Scene and he has the proof that Nobel laureates stole his discovery.

New Approaches to Disaster Relief Challenges

Disaster relief has always been a challenge. NASA, Google,...

3 Legitimate Money Making Methods to Supplement Your Income

In a perfect world, when your landlord raises your...

2016 Predictions by World Renowned Medium and Psychic Lindy Baker

World renowned medium and psychic Lindy Baker is interviewed by The Hollywood Sentinel, discussing psychic power, the spirit world, life after death, areas of concern in 2016, and much more.

Digital Coupon Customers Spending More Than Double At Stores

A new study shows that customers who use digital coupons go shopping more for groceries and other household goods more often and spend more on their shopping trips.

Israel, You Must Muster Unity

But what makes Israel particularly remarkable is the idea that unity does not require sameness.

Choosing The Best Corporate Gifts This Holiday Gifting Season

As the fourth quarter winds down, businesses have a valuable opportunity to express genuine appreciation to the partners, vendors, and customers who fueled their success throughout the year. While branded pens and generic desk accessories o

Islo Raises $15 Million to Address the Next Bottleneck in AI-Powered Software Development

Artificial intelligence is changing the economics of software development,...

Israel Film Festival: 38 Years of Israeli Cinema

Lights, camera, Israel! The 38th Israel Film Festival (IFF) returns to Los Angeles, California, November 18–24, 2026!

Factors to Consider When Looking for the Best Platforms for Trading Synthetic Assets

Choosing one of the best platforms for trading synthetic assets is a crucial decision for a trader interested in synthetic indices. The trading platform or broker you choose will play an integral role in your success as a trader. There are

The Research Document That Changed Meaning in Translation: Why Bilingual Scientific Suppliers Need One Verifiable Record Across Languages

A scientific document can remain visually identical while its meaning changes significantly in translation. A laboratory report may contain the same tables, analytical figures, dates and identifiers in two languages, yet a small difference

The Peptide Study Looked Convincing Until Researchers Asked What It Actually Proved: How Laboratory Findings Become Misleading Human Health Claims

A laboratory experiment produces an impressive result. Researchers observe a measurable biological response after exposing cells to a synthetic peptide. The findings appear in a scientific paper, attract attention online, and eventually bec

Spotlight on M/Y Serdal, a 26m De Birs yacht for sale in Dubai

Serdal offers potential owners something a mere listing can’t, namely the chance to charter her before making an offer. Try before you buy, if you will, this 26-metre superyacht, built by Egyptian shipyard De Birs and delivered to her origi

Related Articles

Popular Categories